Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Moderna Inc
(NQ:
MRNA
)
77.40
-0.19 (-0.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
November 07, 2023
Via
ACCESSWIRE
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 02, 2023
Via
ACCESSWIRE
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
October 30, 2023
Via
ACCESSWIRE
Moderna Named a Top Employer by Science for Ninth Consecutive Year
October 26, 2023
Via
ACCESSWIRE
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
October 24, 2023
Via
ACCESSWIRE
Moderna to Host Second Digital Investor Event on November 8th, 2023
October 19, 2023
Via
ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Making Surprising Moves in Wednesday Session
September 13, 2023
Via
Investor Brand Network
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
September 11, 2023
Via
ACCESSWIRE
Moderna to Host Investor Event - R&D Day and Business Updates
August 30, 2023
Via
ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
August 21, 2023
Via
Investor Brand Network
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
October 12, 2023
Via
ACCESSWIRE
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
October 06, 2023
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth.
Via
MarketBeat
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
October 04, 2023
Via
ACCESSWIRE
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
September 29, 2023
Via
ACCESSWIRE
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
September 14, 2023
Via
ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) is a Leading Gainer in 8/17 Morning Trading
August 17, 2023
Via
Investor Brand Network
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
Via
ACCESSWIRE
Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
July 03, 2023
Via
ACCESSWIRE
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
September 13, 2023
Via
ACCESSWIRE
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
September 11, 2023
Via
ACCESSWIRE
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
September 08, 2023
Via
ACCESSWIRE
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
Via
ACCESSWIRE
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
September 06, 2023
Via
ACCESSWIRE
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
August 17, 2023
Via
ACCESSWIRE
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
July 26, 2023
From
Merck & Co., Inc.
Via
Business Wire
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
July 13, 2023
Via
ACCESSWIRE
$1 Billion Deal For Moderna To Expand Product Pipeline in China
July 06, 2023
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher
Via
MarketBeat
Topics
ETFs
Economy
Exposures
COVID-19
Economy
InvestorNewsBreaks – Cisco Systems Inc. (NASDAQ: CSCO) Featured in Yahoo! Finance Article
July 05, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Economy
Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
July 05, 2023
Via
ACCESSWIRE
Moderna: Declining Performance And Relative Weakness
June 30, 2023
Moderna's value has declined by over 75% from its peak as the world moves on from the COVID-19 pandemic, leading to concerns about its investment appeal.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.